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Long-circulating PEGylated liposomal formulations of doxorubicin (DOX) have shown to increase drug accu-
mulation in tumors and reduce dose-limiting eects of DOX (e.g. cardiotoxicity); however these systems have 
only achieved a moderate improvement in anti-tumor activity due to poor cellular internalization and drug bio-
availability1. We have recently developed an enzyme-sensitive liposome system that exploits the proteolytic 
action of matrix metalloproteases (MMPs), over-expressed in broad range of cancers, to produce the detach-
ment of the PEG-coat and induce a membrane charge shift that will promote their internalization by tumor 
cells and the intracellular drug release2. We aim to demonstrate that DOX formulated into cationic liposomes 
covered with a detachable negatively-charged PEG-coating are ecient nanocarriers to enhance the delivery 
of DOX to tumor cells and improve the anti-tumor activity.
The results show the remarkable capacity of the MMP-triggered liposomes to increase the cellular in-
ternalization of DOX and eciently improve the in vitro growth inhibition of cancer cells compared to 
DOXIL. However, the pharmacokinetic and biodistribution proles demonstrated poor circulating 
properties and tumor accumulation, leading to an unimproved in vivo therapeutic potential compared 
to DOXIL. Further investigation on designing a more stable MMP-sensitive formulation should be car-
ried on in order to ensure long circulating properties of the drug.
1. Barenholz Y. J. Control. Release. 2012 (160) 117-134.
 
2. Gjetting T., Jølck R., Andresen T. L. Adv. Healthc. Mater. 
2014 (3) 1107-1118.
3. Laginha K. M., Verwoert S., Charrois G. J. R., Allen T. M. 
Clin. Cancer Res. 2005 (19) 6944-6949.
The MMP-sensitive formulation increased the uptake of the liposomes by the cells upon proteolitic activation, 
resulting in an increased intracellular delivery of DOX and improved cytotoxic activity as compared with DOXIL 
(Fig. 1-3). The DOX-loaded MMP-sensitive liposomes showed a reduced blood circulation prole as compared 
with DOXIL (Fig. 4), suggesting a premature leakage of DOX from the carrier and/or fast removal by the RES. 
Thus, DOX levels found in the tumor were reduced whereas in the spleen were signicatly higher. Encapsula-
tion of DOX within MMP-sensitive liposomes resulted in slightly better tumor growth inhibition compared to 
the Free DOX but failed to provide similar therapeutic ecy as DOXIL.     
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In vitro cell uptake and growth inhibition of DOX formulated in MMP-sensitive liposomes
Figure 3. In vitro anti-proliferative eect of 
free DOX, DOXIL and DOX-loaded in 
MMP-sensitive liposomes either activated or 
not, on CT26 cancer cells. The cells were incu-
bated with the compounds for 4 h, washed 
with complete medium and further incubat-
ed for additional 68 h. Then the proliferation 
was assessed by MTS assay.
Figure 4. Pharmacokinetics and biodistribution (upper panel) of DOX-loaded MMP-sensitive 
liposomes. CT26 tumor-bearing Balb/c mice were injected with 10mg/kg of Free DOX, DOXIL 
and DOX-loaded MMP-sensitive liposomes. Blood samples were taken at 0.5 h, 5 h and 24 h, 
then the animals were sacried and tissues were dissected. DOX was extracted following a 
acidied isopropanol extraction method3 and detected uorescently (ex.470nm/em.590nm).
To assess the therapeutic ecacy of MMP-sensitive liposomes, tumor growth and survival 
rates (lower panel) were monitored after mice received 4 injections of 4mg/kg (qweek) of 
saline solution, Free DOX, DOXIL and DOX-loaded MMP-liposomes. 
Figure 2. Confocal imaging of xed CT26 cancer cells treated 
during 4 h with DOXIL or MMP-activated liposomes loaded 
with DOX. Both formulations included DOPE-ATTO655 
(0.05mol%) as uorescent label. The samples were excited with 
an argon (488 nm) and HeNe (633 nm) lasers. A) BF image; B) 
DOX signal (560-620nm); C) DOPE-ATTO655 signal 
(665-720nm); D) overlay image. Scale bars are 50 µm.
Figure 1. In vitro uptake of free DOX, 
DOXIL and DOX-loaded MMP-sensi-
tive liposomes on CT26 cancer cells 
after 4 h incubation. FACS was used 
to detect the cell uptake of lipid 
DOPE-ATTO655 in FL6 (660±20nm) 
and DOX in FL2 (575±30nm).
In vivo evaluation of DOX-loaded MMP-sensitive liposomes
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